Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

705 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response.
Pasqualoni M, Orlandi A, Palazzo A, Garufi G, Cannizzaro MC, Pontolillo L, Pannunzio S, Cutigni C, Sollena P, Federico F, Bria E, Tortora G. Pasqualoni M, et al. Among authors: tortora g. Front Oncol. 2023 Mar 9;13:1067264. doi: 10.3389/fonc.2023.1067264. eCollection 2023. Front Oncol. 2023. PMID: 36969030 Free PMC article.
A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants.
Giacò L, Palluzzi F, Guido D, Nero C, Giacomini F, Duranti S, Bria E, Tortora G, Cenci T, Martini M, De Paolis E, Onori ME, De Bonis M, Normanno N, Scambia G, Minucci A. Giacò L, et al. Among authors: tortora g. Cancers (Basel). 2022 Dec 13;14(24):6152. doi: 10.3390/cancers14246152. Cancers (Basel). 2022. PMID: 36551638 Free PMC article.
The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
Mastrantoni L, Orlandi A, Palazzo A, Garufi G, Fabi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Among authors: tortora g. EClinicalMedicine. 2023 Jan 20;56:101824. doi: 10.1016/j.eclinm.2023.101824. eCollection 2023 Feb. EClinicalMedicine. 2023. PMID: 36713467 Free PMC article.
Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
Salvatore L, Bensi M, Vivolo R, Zurlo IV, Dell'Aquila E, Grande R, Anghelone A, Emiliani A, Citarella F, Calegari MA, Ribelli M, Basso M, Pozzo C, Tortora G. Salvatore L, et al. Among authors: tortora g. Front Oncol. 2023 Feb 21;13:1125013. doi: 10.3389/fonc.2023.1125013. eCollection 2023. Front Oncol. 2023. PMID: 36895480 Free PMC article.
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy.
Garufi G, Carbognin L, Sperduti I, Miglietta F, Dieci MV, Mazzeo R, Orlandi A, Gerratana L, Palazzo A, Fabi A, Paris I, Franco A, Franceschini G, Fiorio E, Pilotto S, Guarneri V, Puglisi F, Conte P, Milella M, Scambia G, Tortora G, Bria E. Garufi G, et al. Among authors: tortora g. Ther Adv Med Oncol. 2023 Mar 14;15:17588359221138657. doi: 10.1177/17588359221138657. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36936199 Free PMC article.
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials.
Mastrantoni L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, Pannunzio S, Cannizzaro MC, Di Bello A, Fabi A, Palazzo A, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Among authors: tortora g. Ther Adv Med Oncol. 2023 May 29;15:17588359231173180. doi: 10.1177/17588359231173180. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37284523 Free PMC article.
Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis.
Mastrantoni L, Beccia V, Caira G, Trovato G, Calegari MA, Basso M, Salvatore L, Pozzo C, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Among authors: tortora g. Crit Rev Oncol Hematol. 2023 Nov;191:104106. doi: 10.1016/j.critrevonc.2023.104106. Epub 2023 Sep 1. Crit Rev Oncol Hematol. 2023. PMID: 37659764 Free article. Review.
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Vita E, Stefani A, Piro G, Mastrantoni L, Cintoni M, Cicchetti G, Sparagna I, Monaca F, Horn G, Russo J, Barone D, Di Salvatore M, Trisolini R, Lococo F, Mazzarella C, Cancellieri A, Carbone C, Larici AR, Mele MC, Pilotto S, Milella M, Tortora G, Bria E. Vita E, et al. Among authors: tortora g. Cancer Immunol Immunother. 2023 Nov;72(11):3803-3812. doi: 10.1007/s00262-023-03533-0. Epub 2023 Sep 5. Cancer Immunol Immunother. 2023. PMID: 37668709 Free PMC article.
Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer.
Agostini A, Guerriero I, Piro G, Quero G, Roberto L, Esposito A, Caggiano A, Priori L, Scaglione G, De Sanctis F, Sistigu A, Musella M, Larghi A, Rizzatti G, Lucchetti D, Alfieri S, Sgambato A, Bria E, Bizzozero L, Arena S, Ugel S, Corbo V, Tortora G, Carbone C. Agostini A, et al. Among authors: tortora g. J Transl Med. 2023 Nov 23;21(1):843. doi: 10.1186/s12967-023-04733-z. J Transl Med. 2023. PMID: 37996891 Free PMC article.
705 results